详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Hematopoietic stem cell transplantation activity in China 2022-2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group

7| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. [2]Hebei Yanda Lu Daopei Hospital, Langfang, Hebei & Beijing Lu Daopei Hospital, Beijing, China. [3]The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Disease, Soochow, China. [4]The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. [5]State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. [6]Chinese PLA General Hospital, Beijing, China. [7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. [8]Xinqiao Hospital of Army Medical University, Chongqing, China. [9]Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China. [10]Fujian Medical University Union Hospital, Fujian Provincial Key Laboratory of Hematology, Fujian Institute of Hematology, Fuzhou, China. [11]West China Hospital, Sichuan University, Chengdu, Sichuan, China. [12]The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. [13]Nanfang Hospital, Guangzhou, China. [14]Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. [15]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [16]Xiangya Hospital, Central South University, Changsha, Hunan, China. [17]Nanfang-Chunfu Children's Institute of Hematology, Taixin Hospital, Dongguan, China. [18]Shanghai Institute of Hematology, Ruijn Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [19]Shenzhen Children's Hospital, Shenzhen, Guangdong, China. [20]The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

出处：

DOI：

ISSN：

摘要：

Over past two years, a total of 39,918 hematopoietic stem cell transplantation (HSCT) cases were reported, with 18,194 and 21,714 transplants performed in 2022 and 2023, respectively. Autologous HSCT accounted for 6562 cases (31%) in 2022, while allogeneic HSCT comprised 12,632 cases (69%). In 2023, the number of allogeneic HSCTs exceeded 15,000, maintaining a 69% share. Participation in the 2022 and 2023 surveys included 193 and 212 transplantation teams, respectively, from 27 provinces, municipalities, or autonomous regions. The leading indication of HSCT was acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and mixed phenotype acute leukemia, with a total of 17,421 cases. AML was the most common disease (10,339, 38%) for allogeneic HSCT, which was followed by ALL (5925 cases, 21%). Peripheral blood emerged as the primary source of stem cell grafts, utilized in 54% of matched sibling donor transplants and 77% of haploidentical donor transplants. The BuCy-based conditioning regimen was the most prevalent, used in 53% of allogeneic HSCT cases in the past two years. This survey offers a comprehensive overview of the current HSCT landscape and serves as a valuable resource for clinical practice.© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区医学

小类 | 2 区移植 3 区血液学 3 区免疫学 3 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 HEMATOLOGY Q1 ONCOLOGY Q1 TRANSPLANTATION Q2 IMMUNOLOGY

影响因子： 4.5 最新[2023版] 4.5 最新五年平均 4.5 出版当年[2023版] 0 出版当年五年平均 4.5 出版前一年[2023版]

第一作者：

第一作者机构： [1]Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：